-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Neuphoria Therapeutics Inc. quarterly/annual Income Tax Expense (Benefit) history and change rate from 2023 to Q3 2025.
- Neuphoria Therapeutics Inc. Income Tax Expense (Benefit) for the quarter ending 30 Sep 2025 was -$34,793.000, a 73.7% increase year-over-year.
- Neuphoria Therapeutics Inc. Income Tax Expense (Benefit) for the twelve months ending 30 Sep 2025 was -$370,972.000, a 101% decline year-over-year.
- Neuphoria Therapeutics Inc. annual Income Tax Expense (Benefit) for 2025 was -$468,366.000, a 436% decline from 2024.
- Neuphoria Therapeutics Inc. annual Income Tax Expense (Benefit) for 2024 was -$87,320.000, a 37.3% increase from 2023.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Change (%)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Change (%)